Bronkiektasis

01Pathophysiology

Bronchiectasis is the end result of a vicious cycle involving three interdependent elements: airway obstruction, chronic infection, and inflammatory tissue destruction. Understanding this cycle is central to answering exam questions because almost every clinical feature and management decision traces back to it.

The cycle begins when an initial insult damages the bronchial wall or impairs mucociliary clearance. This insult may be an infection (e.g., childhood pertussis, tuberculosis), a genetic defect in ciliary motility (primary ciliary dyskinesia), abnormal mucus viscosity (cystic fibrosis), or an immune deficiency that prevents effective pathogen clearance. Once clearance is impaired, mucus stasis occurs, creating a favorable environment for bacterial colonization. The organisms most commonly implicated are Haemophilus influenzae (early disease) and Pseudomonas aeruginosa (advanced or long-standing disease). The presence of Pseudomonas on sputum culture is a prognostic marker associated with more rapid decline in lung function.

Persistent bacterial colonization triggers a neutrophil-dominant inflammatory response. Neutrophils release proteases (particularly elastase) and reactive oxygen species that damage the elastic and muscular layers of the bronchial wall. This structural destruction causes the airway to become permanently dilated and floppy, losing its ability to effectively propel mucus outward. The dilated, damaged airway then traps even more mucus, perpetuating infection and further inflammation. This is why the condition is irreversible once established.

The chronic inflammation also leads to bronchial artery hypertrophy. These hypertrophied systemic vessels are fragile and prone to rupture, which explains why hemoptysis is a common and sometimes life-threatening complication of bronchiectasis. On exam, a patient with known bronchiectasis presenting with sudden large-volume hemoptysis should prompt concern for bronchial artery bleeding, and the next best step is bronchial artery embolization if the bleeding is severe.

The pathophysiology also explains the physical exam findings. Coarse crackles result from air passing through mucus-filled, dilated airways. Digital clubbing develops in chronic disease due to prolonged hypoxemia and circulating growth factors. Foul-smelling sputum reflects anaerobic bacterial overgrowth in stagnant mucus pools.

02Classification and Clinical Manifestation

Morphologic Classification (Reid Classification)

This classification is based on HRCT appearance and carries prognostic significance.

Clinical Manifestation by Disease Phase

Distribution Pattern as a Clue to Etiology

03Diagnostic Workup

The best initial test when bronchiectasis is suspected clinically is a chest X-ray. However, CXR has limited sensitivity; it can appear normal in mild or early cases. When the clinical picture is suggestive (chronic productive cough, recurrent infections, hemoptysis) and the CXR is either abnormal or inconclusive, the next step is HRCT of the chest without contrast.

HRCT is the gold standard for diagnosing bronchiectasis. The hallmark finding is the signet ring sign, where the dilated bronchus (the "ring") is seen adjacent to its accompanying pulmonary artery (the "stone"), and the bronchus is larger than the artery. Normally, the broncho-arterial ratio is approximately 1:1; in bronchiectasis, this ratio exceeds 1. Other HRCT findings include airways visible within 1 cm of the costal pleura (normally airways taper and are not visible this far out) and the "tree-in-bud" pattern suggesting mucoid impaction of small airways.

Once the diagnosis is confirmed, the workup shifts to identifying the underlying cause, because treatment of the etiology can slow disease progression. This is a commonly tested concept. Every patient with newly diagnosed bronchiectasis should have: sputum cultures (to guide antibiotic therapy), serum immunoglobulin levels (to rule out CVID), and a sweat chloride test in patients under 40 or those with upper-lobe predominant disease (to rule out cystic fibrosis). If the distribution is upper-lobe predominant and there is peripheral eosinophilia, ABPA workup is warranted. If situs inversus or chronic sinusitis accompanies the bronchiectasis, evaluate for primary ciliary dyskinesia (Kartagener syndrome).

Pulmonary function testing is performed to assess baseline severity and monitor progression. The expected pattern is obstructive ($\downarrow FE{V}_1\mathrm{/}FVC\backslash downarrow\; FEV\_1/FVC$ ratio), though advanced disease can produce a mixed pattern.

04Management and Treatment

Airway clearance is the cornerstone of bronchiectasis management and should be prescribed for every patient regardless of severity. The goal is to break the vicious cycle by mechanically removing stagnant, infected mucus. This is performed at least once or twice daily. Options include manual chest percussion with postural drainage, oscillatory positive expiratory pressure (PEP) devices, high-frequency chest wall oscillation vests, and active cycle breathing techniques. On exam, if asked about the "most important non-pharmacologic intervention," airway clearance is the answer.

For acute exacerbations, the standard antibiotic course is 14 days (longer than typical community-acquired pneumonia treatment). Initial empiric coverage should be guided by prior sputum culture results. In patients without a history of Pseudomonas, amoxicillin-clavulanate is a reasonable first-line oral agent. In patients with documented or suspected Pseudomonas colonization, oral ciprofloxacin is used for mild to moderate exacerbations, and IV anti-pseudomonal agents (piperacillin-tazobactam, cefepime, or meropenem) are reserved for severe exacerbations or treatment failure.

Macrolide prophylaxis with azithromycin is one of the most testable management points. It is indicated in patients with three or more exacerbations per year despite optimized airway clearance. The benefit comes primarily from the drug's anti-inflammatory and immunomodulatory effects (reduction of neutrophilic inflammation, inhibition of biofilm formation), not purely from its antibacterial activity. Before initiating long-term azithromycin, sputum cultures must be sent for acid-fast bacilli (AFB) to rule out nontuberculous mycobacterial (NTM) infection, because macrolide monotherapy in NTM disease promotes resistance and complicates future treatment.

Inhaled corticosteroids are generally not recommended for bronchiectasis unless there is coexisting asthma or ABPA. Mucolytics such as hypertonic saline (7% nebulized) can be used to improve mucus clearance, but recombinant DNase (dornase alfa) is only indicated in cystic fibrosis-related bronchiectasis and is actually harmful in non-CF bronchiectasis. This is a commonly tested distinction.

For life-threatening hemoptysis, the immediate step is hemodynamic stabilization, positioning the patient with the bleeding side down, and pursuing bronchial artery embolization. Surgical resection is a second-line option if embolization is unsuccessful or technically not feasible.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on bronchiectasis questions is by confusing it with COPD or chronic bronchitis when the vignette describes a patient with chronic productive cough and obstructive PFTs. The discriminating clue is the character and volume of sputum: bronchiectasis produces large quantities of purulent, often foul-smelling sputum ("cupfuls per day"), while COPD and chronic bronchitis produce modest amounts of mucoid sputum. If the vignette mentions "daily production of large volumes of purulent sputum" or "recurrent pneumonias in the same anatomic distribution," that is the signal pointing toward bronchiectasis rather than COPD.

Another classic trap involves the diagnostic test. Students often select bronchoscopy or CXR as the confirmatory test. The gold standard is always HRCT of the chest. CXR is the initial screening tool but lacks sensitivity. Bronchoscopy has a role in ruling out endobronchial obstruction in focal bronchiectasis but is not the confirmatory imaging modality.

A third trap involves dornase alfa (recombinant DNase). Students who associate this drug with "mucus clearance in bronchiectasis" may select it as a correct treatment. Dornase alfa is only indicated in cystic fibrosis-related bronchiectasis. In non-CF bronchiectasis, it has been shown to worsen outcomes and is contraindicated. Hypertonic saline (nebulized 7%) is the appropriate mucolytic alternative in non-CF disease.

A fourth high-yield pearl involves macrolide prophylaxis. Before starting long-term azithromycin, you must rule out NTM infection with AFB sputum cultures. Macrolide monotherapy in undiagnosed NTM disease leads to macrolide resistance, making subsequent NTM treatment far more difficult. This sequencing question ("what should you do before starting azithromycin prophylaxis?") is a favorite exam setup.

Finally, when a bronchiectasis patient presents with acute, large-volume hemoptysis, the next best step is not intubation or surgical consultation as the initial move. The answer is bronchial artery embolization, which is both diagnostic and therapeutic for identifying and occluding the hypertrophied bronchial artery causing the bleed. Surgical resection is reserved for failure of embolization.

The core competency being tested in bronchiectasis questions is the ability to (1) recognize the disease through its hallmark presentation of voluminous purulent sputum with recurrent infections, (2) correctly identify HRCT as the confirmatory test, (3) distinguish it from COPD and chronic bronchitis, (4) identify and treat the underlying etiology, and (5) apply the correct pharmacologic nuances (dornase alfa only in CF, macrolide prophylaxis only after ruling out NTM, anti-pseudomonal coverage in advanced disease).